Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.

  title={Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.},
  author={Eva M Vivian},
  journal={The Diabetes educator},
  volume={41 1 Suppl},
PURPOSE The purpose of this review article is to provide guidance to clinicians and diabetes educators regarding the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors as a therapeutic option for the treatment of patients with type 2 diabetes mellitus (T2DM). METHODS The PubMed database was searched through February 2015 to identify clinical trials and meta-analyses evaluating the use of the SGLT2 inhibitors canagliflozin, dapagliflozin, and empagliflozin administered as monotherapy or… CONTINUE READING


Publications referenced by this paper.
Showing 1-10 of 57 references

Approaches to glycemic treatment . Sec 7

  • SE Inzucchi, RM Bergenstal, JB Buse
  • Diabetes Care
  • 2015

Efficacy and safety of canagliflozin , an inhibitor of sodiumglucose cotransporter 2 , when used in conjunction with insulin therapy in patients with type 2 diabetes

  • B Neal, V Perkovic, D deZeeuw
  • Diabetes Care
  • 2015

Glycemic targets . Sec 6

  • V Vallon, KA Platt, R Cunard
  • Diabetes Care
  • 2015

Similar Papers

Loading similar papers…